RAM
SNDX icon

Riggs Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Riggs Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-26
Closed -$619 – 756
2024
Q1 		$619 Buy
+26
New +$580 ﹤0.01% 499

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Riggs Asset Management's SNDX Position: Q2 2024 in Review

Riggs Asset Management sold out of Syndax Pharmaceuticals (SNDX) in Q2 2024, closing a stake of 26 shares — an estimated $619 sold.

Riggs Asset Management first reported a position in SNDX in Q1 2024 and held it in 1 quarter. The position peaked at $619 in Q1 2024. 196 funds tracked by Wall St. Rank hold SNDX as of Q2 2024.

  • Riggs Asset Management reported no remaining Syndax Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Riggs Asset Management sold 26 Syndax Pharmaceuticals shares in Q2 2024, an estimated $619.
  • Riggs Asset Management first reported a position in Syndax Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Riggs Asset Management's Syndax Pharmaceuticals position peaked at $619 in Q1 2024.
  • 196 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2024.

Based on Riggs Asset Management's 13F filing for Q2 2024, filed 29 Jul 2024.